Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs. Built on our proprietary Retinol Binding Protein 4 (RBP4) IP portfolio, our clinical pipeline includes Tinlarebant (LBS-008), an oral therapy currently in late-stage clinical trials (including the Phase 3 DRAGON and PHOENIX studies) for Stargardt disease (STGD1) and Geographic Atrophy (GA) in dry AMD.
At Belite Bio, we are dedicated to developing innovative solutions to treat untreatable conditions and prevent vision loss in patients worldwide. As an emerging, agile organization, we offer a fast-paced environment where dynamic self-starters thrive. Operating at the forefront of drug development means our team members wear multiple hats, roll up their sleeves, and bring deep personal dedication to every project. If you are energized by a high-impact, hands-on culture where your effort directly shapes our growth and mission, you will find a rewarding home here.